Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Man, Chi Yin; Cheung, Ian T.F.; Cameron, Peter A.; Rainer, Timothy (2007)
Publisher: Elsevier
Languages: English
Types: Article
Subjects: R1
Study objective\ud \ud We compare the analgesic efficacy and adverse effects of oral prednisolone/acetaminophen and oral indomethacin/acetaminophen combination therapy in the treatment of acute goutlike arthritis in patients presenting to an emergency department (ED).\ud \ud Methods\ud \ud This is a double-blind, randomized, controlled study in a university hospital emergency department (ED) in the New Territories of Hong Kong. Patients older than 17 years and presenting between February 1, 2003, and June 30, 2004, with a clinical diagnosis of goutlike arthritis were randomized to receive either oral prednisolone/acetaminophen or oral indomethacin/acetaminophen combination therapy. Primary outcome measures were pain scores, time to resolution of symptoms and signs, and adverse effects. Secondary outcome measures were the need for additional acetaminophen and relapse rate.\ud \ud Results\ud \ud There were 90 patients randomized: 46 patients to the indomethacin group and 44 patients to the prednisolone group. Baseline characteristics, including pain scores, were similar in the 2 groups. Both treatment groups had a similar decrease in pain score in the ED. The mean rate of decrease in pain score with activity for indomethacin was −1.7±1.6 (SD) mm per day and for prednisolone was −2.9±2.0 (SD) mm per day (mean difference 1.2 mm/day; 95% confidence interval 0.4 to 2.0 mm/day; P=.0026). Although these differences were statistically significant, at no time was the difference in mean pain score greater than 13 mm. Therefore, it is unclear whether these differences are clinically significant. The mean total dose of acetaminophen consumed by the prednisolone group was significantly more than in the indomethacin group (mean 10.3 g, range 1 to 21 g versus mean 6.4 g, range 1 to 21 g). Twenty-nine patients in the indomethacin group and 12 patients in the prednisolone group experienced adverse effects (P<.05). The commonest adverse effects in the indomethacin group were nausea, indigestion, epigastric pain, dizziness, and gastrointestinal bleeding (N=5; 11%). None of the patients in the prednisolone group developed gastrointestinal bleeding. The relapse rate for both groups was similar.\ud \ud Conclusion\ud \ud In the treatment of acute goutlike arthritis, oral prednisolone/acetaminophen combination is as effective as oral indomethacin/acetaminophen combination in relieving pain but is associated with fewer adverse effects.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Kim KY, Ralph SH, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25: 1593-1617.
    • 2. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995;48:1153-1158.
    • 3. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-2406.
    • 4. British National Formulary. 2005;49:494-495.
    • 5. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal antiinflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3:98-101.
    • 6. James DS. The multisystem adverse effects of NSAID therapy. J Am Osteopath Assoc. 1999;99(11 suppl):S1-S7.
    • 7. Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Pract Res Clin Gastroenterol. 2001;15:739-753.
    • 8. McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des. 2000;6:1693-1724.
    • 9. Jelley MJ, Wortmann R. Practical steps in the diagnosis and management of gout. Biodrug. 2000;14:99-107.
    • 10. Fam AG. Strategies and controversies in the treatment of gout and hyperuricaemia. Baillieres Clin Rheumatol. 1990;4:177-192.
    • 11. Garcia R, Luis A, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drug. Lancet. 1994;343:769-772.
    • 12. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093-2099.
    • 13. Ferrannini E, Pentimone F. Marrow aplasia following colchicine treatment for gouty arthritis. Clin Exp Rheumatol. 1984;2: 173-175.
    • 14. Roberts WN, Liang MH, Stern SH. Colchicine in acute gout: reassessment of risks and benefits. JAMA. 1987;257: 1920-1922.
    • 15. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? the results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-304.
    • 16. Groff GD, Franck WA, Roddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19:329-336.
    • 17. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20:111-113.
    • 18. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotrophic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rhematol. 1994;21: 1325-1327.
    • 19. Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic steroids. Cochrane Database Syst Rev. 2001;1:CD002178.
    • 20. Huskisson EC. Measurement of pain. Lancet. 1974;2: 1127-1131.
    • 21. Gaddis GM, Salomone JA, Watson WA. Most linear analogue pain data should be analyzed by nonparametric statistical techniques [abstract]. Ann Emerg Med. 1992;21:629.
    • 22. Bland M. An Introduction to Medical Statistics. 2nd ed. Oxford, England: Oxford Publications; 1995.
    • 23. Matthews JNS, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ. 1990;300:230-235.
    • 24. Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27:485-489.
    • 25. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64:2399-2416.
    • 26. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996;63:248-254.
    • 27. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20:111-113.
    • 28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000; 343:1520-1528.
    • 29. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-1492.
    • 30. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50:598-606.
    • 31. Graham DJ, Capmen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet. 2005; 365:475-481.
    • 32. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142:481-489.
    • 33. Li YM, Wang SX, Gao HS, et al. Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence [in Chinese]. Zhonghua Yi Xue Za Zhi. 2004;84:1348-1353.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article